Gene-editing technology CRISPR is projected to have a fast revenue growth over the next five years, as revenues grow from $779 million in 2017 to $5.2 billion in 2023.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
With Brexit discussions still ongoing, GlaxoSmithKline’s chief executive, Emma Walmsley is taking no chances as she urges the government to sign a two-year transition deal by April to ensure the industry can cope.
Gilead Sciences has moved closer to capturing more of the multibillion-dollar HIV drug market, with its recent drug approval from the U.S. Food and Drug Administration.
Pfizer has announced a two-year collaboration with DL Medicine, intended to produce new chemical entities against preselected targets from multiple therapeutic areas.
European drugmaker and the world’s biggest insulin maker, Novo Nordisk, wants to prove it can transform the diabetes market with a pill.
If you aren’t aware of PubMed Commons, it is a tool that allows scientists to comment on articles indexed in the agency’s popular PubMed database of biomedical literature. Well, after five years its closed its doors.
UK’s biggest drugmaker, GlaxoSmithKline is poised to post record sales of over £30 billion for the first time, in Chief Executive Emma Walmsley’s first set of full-year results this week.
Skyhawk Therapeutics, focused on the discovery and development of small molecule therapeutics that correct RNA expression, has announced the close of $8 million in seed funding led by major family and biotech investors.
After approving 46 novel drugs in addition to several biological license applications back in 2017, could this year be another big year for approvals?
Illumina Ventures- and Merck-backed DNA Script have gotten one step closer to its vision of higher speed, higher efficiency, harsh-chemical free DNA synthesis.
The decision didn’t come overnight. According to reports, the heads of each company — Jamie Dimon, Warren Buffet and Jeff Bezos — have chatted for years about how to fix the problem of high costs and a broken healthcare system.
Sphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, has today announced the expansion of its international commercial operations.